Nasdaq
$61.44▲ 1.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $8.87BShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
53- 10.9After-hours26.10.10 05:428-KKey event#●●●#●●●#●●●
Vaxcyte, Inc.
Vaxcyte completed a concurrent offering on October 9, 2026, issuing 7,412,500 shares of common stock and 400,000 pre-funded warrants, alongside $575 million in 1.50% convertible senior notes due 2032. The company raised approximately $544.3 million in net proceeds from the equity offering and $558.7 million from the debt offering, after deducting underwriting discounts and estimated expenses.…more
$61.44+1.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8After-hours26.10.09 05:34424B5Offering
Vaxcyte, Inc.
Vaxcyte is raising capital through an offering of $500 million in 1.50% convertible senior notes due 2032, with an additional $75 million over-allotment option granted to underwriters. Concurrently, the company is conducting an equity offering of 7,412,500 shares of common stock and pre-funded warrants to purchase 400,000 shares.…more
$61.44+1.78%vs prev closeView filingShare - 10.8After-hours26.10.09 05:30424B5Offering
Vaxcyte, Inc.
Vaxcyte is raising approximately $499.99 million through an offering of 7,412,500 shares of common stock and pre-funded warrants to purchase 400,000 shares. The company is concurrently offering $500 million in convertible senior notes, with proceeds from both offerings intended for clinical development and general corporate purposes.…more
$61.44+1.78%vs prev closeView filingShare
52 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9After-hours26.10.10 05:05Bullish#●●●#●●●#●●●
Vaxcyte Completes $1.15 Billion Public Offering of Stock and Convertible Notes…more
Vaxcyte has closed a $1.15 billion offering of common stock and convertible senior notes to fund clinical development and commercialization efforts. The significant dilution resulting from this capital raise may be viewed negatively by existing shareholders.…more
$61.44+1.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.8Pre-market26.10.08 18:59
●●●●●●●● ●●●●● ●●●●●●
Russian authorities have officially denied media reports regarding a second case of illness in the Siberia region. This development does not contain specific economic data or corporate information that would impact the markets.…more
$61.44+1.78%vs prev closeShareBenzinga - 10.7Overnight26.10.07 15:58
●●●●●●●● ●●●●● ●●●●●●
Vaxcyte is raising capital through a concurrent offering of common shares and convertible notes. This financing structure introduces potential dilution for existing shareholders.…more
$61.44+1.78%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report